This is proof of concept, phase I randomized controlled trial studying a short acting non-opioid anesthetic, bupivacaine to improve post-operative pain in gynecologic surgery patients. Patients who are undergoing minimally invasive (laparoscopic or robotic) hysterectomy will be randomized to receive no uterosacral injection, normal saline uterosacral injection, or 0.25% bupivacaine uterosacral injection just prior to colpotomy (incision around the cervix and removal of uterus) during minimally invasive hysterectomy.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Enrollment
180
Bupivicaine injection into uterosacral ligaments prior to colpotomy
Johns Hopkins Hospital
Baltimore, Maryland, United States
Howard County General Hospital
Columbia, Maryland, United States
Difference in post-operative opioid usage with the use of uterosacral ligament bupivacaine injection
Total morphine equivalents of opioids in the first 7 days after surgery will be assessed to look for a statistically significant difference
Time frame: 7 days post-op
Difference in Visual analog scores (VAS) scores following uterosacral ligament bupivicaine injection
Patient will report VAS scores daily until post-op day 7 on a scale of 1-10 with higher scores indicating higher pain severity. The investigators will be looking for a statistically significant difference between the treatment and placebo vs. sham group.
Time frame: 7 days post-op
Time to first bowel movement following uterosacral ligament bupivicaine injection
Patients will record when they resume normal bowel function on a pill diary post-operatively
Time frame: 7 days post-op
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.